Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Precision Medicine for High-Risk Gene Fusions in Pediatric AML: a focus on KMT2A, NUP98, and GLIS2 Rearrangements

Grace Egan, Sarah K Tasian

Blood blood.2024026598.

https://doi.org/10.1182/blood.2024026598

Published: 2025

Journal Articles

Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Blood blood.2024026482.

https://doi.org/10.1182/blood.2024026482

Published: 2025

Includes: Supplemental data

Journal Articles

How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adults

Thai Hoa Tran, Sarah K. Tasian

Blood (2025) 145 (1): 20–34.

https://doi.org/10.1182/blood.2023023153

Published: 2025

Journal Articles

Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML

Jeremy Grenier, Sarah K. Tasian, Elliot Stieglitz, Zied Abdullaev, Gerald Wertheim, Marilyn M. Li, Charles A Phillips

Blood (2024) 144 (Supplement 1): 6739.

https://doi.org/10.1182/blood-2024-203951

Published: 2024

Journal Articles

APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A- rearranged , NUP98- rearranged , or NPM1- mutant Acute Leukemias

Elisabeth Salzer, Janine Stutterheim, Branko Cuglievan, Blake E. Tomkinson, Mollie Leoni, Harm Van Tinteren, Alwin D.R. Huitema, Marieke Willemse, Gwen L Nichols, Francisco Bautista, Sarah K. Tasian, Todd M Cooper, Christian Zwaan

Blood (2024) 144 (Supplement 1): 4265.3.

https://doi.org/10.1182/blood-2024-204583

Published: 2024

Journal Articles

PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML

Alexandra McLean Stevens, Maureen M. O'Brien, Xiaowei Liu, Charles G Minard, Olga Militano, Joel M Reid, Shyamala Navada, Todd M Cooper, Sarah K. Tasian, Elizabeth Fox, Brenda J. Weigel

Blood (2024) 144 (Supplement 1): 4265.4.

https://doi.org/10.1182/blood-2024-207907

Published: 2024

Journal Articles

Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

Blood (2024) 144 (Supplement 1): 2828.1.

https://doi.org/10.1182/blood-2024-201871

Published: 2024

Journal Articles

KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Venkata Sesha Sai Abhinav Ayyadevara, Gerald Wertheim, John Chukinas, Joseph Loftus, Sung June Lee, Anil Kumar, Srividya Swaminathan, Rahul S Bhansali, Wayne Childers, Huimin Geng, Thomas A Milne, Xianxin Hua, Kathrin M. Bernt, Thierry Besson, Junwei Shi, John D. Crispino, Martin P Carroll, Sarah K. Tasian, Christian Hurtz

Blood (2024) 144 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2024-206134

Published: 2024

Journal Articles

Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial

Michele S. Redell, Robert Gerbing, Todd A. Alonzo, Jim Wang, Maureen O'Brien, Sarah K. Tasian, Matthew A. Kutny, Todd M Cooper

Blood (2024) 144 (Supplement 1): 4233.

https://doi.org/10.1182/blood-2024-200978

Published: 2024

Journal Articles

Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2 -Rearranged Ph-like and Down Syndrome ALL

Tommaso Balestra, Lisa M Niswander, Asen Bagashev, Joseph P Loftus, Savannah L Ross, Robert K Chen, Samantha M McClellan, Jacob J Junco, Diego Alberto Barcenas-Lopez, Karen R Rabin, Terry J Fry, Sarah K. Tasian

Blood (2024) 144 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2024-208383

Published: 2024

Journal Articles

A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma

Peter Gordon, Robin Williams, Jason Ostergaard, Joseph Muretta, Bridget S. Wilson, Luke Lambert, Timothy P. Singleton, Sarah K. Tasian, Stuart S. Winter

Blood (2024) 144 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2024-199853

Published: 2024

Journal Articles

A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia

Muneera Alhaddad, Roberta Buono, Van Thu Huynh, Sarah K. Tasian, David A Fruman

Blood (2024) 144 (Supplement 1): 2789.

https://doi.org/10.1182/blood-2024-206734

Published: 2024

Journal Articles

Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias

Lisa M Niswander, Samantha McClellan, Diego Alberto Barcenas-Lopez, Michael Yarnell, Shubhmita Bhatnagar, Terry J Fry, Sarah K. Tasian

Blood (2024) 144 (Supplement 1): 370.

https://doi.org/10.1182/blood-2024-206467

Published: 2024

Journal Articles

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Tommaso Balestra, Camilo Arenas Merizalde, Robert K Chen, John Roach, Brian Bowser, Rachelle Salomon, Anthony Welch, Bonnie Yates, Kristin Schaller, Michael R Verneris, Susanne H.C. Baumeister, Emily M. Hsieh, M. Eric Kohler, Katherine Tarlock, Steven M. Devine, Richard Aplenc, Nirali N. Shah, Terry J Fry, Sarah K. Tasian

Blood (2024) 144 (Supplement 1): 369.

https://doi.org/10.1182/blood-2024-211517

Published: 2024

Journal Articles

Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL

Linda Resar, Jung-Hyun Kim, Li Z Luo, Katharina Hayer, Camilo Arenas Merizalde, Leslie Cope, Andrei Thomas-Tikhonenko, Sarah K. Tasian

Blood (2024) 144 (Supplement 1): 1361.

https://doi.org/10.1182/blood-2024-211514

Published: 2024

Journal Articles

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Sarah Elitzur, Ruth Shiloh, Jan L. C. Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Thomas Lehrnbecher, Sarah K. Tasian, Oussama Abla, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Nicole Bodmer, Triantafyllia Brozou, Francesco Ceppi, Liliia Chugaeva, Luciano Dalla Pozza, Stephane Ducassou, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Stefanie Junk, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Nizar Mahlaoui, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Marion Strullu, Thai Hoa Tran, Marek Ussowicz, Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, A. Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Veronique Minard-Colin, Kjeld Schmiegelow, Ronit Nirel, Andishe Attarbaschi, Arndt Borkhardt

Blood (2024) 144 (11): 1193–1205.

https://doi.org/10.1182/blood.2024024283

Published: 2024

Includes: Supplemental data

Journal Articles

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain

Inge van Outersterp, Sarah K. Tasian, Caitlin E. J. Reichert, Aurélie Boeree, Hester A. de Groot-Kruseman, Gabriele Escherich, Judith M. Boer, Monique L. den Boer

Blood (2024) 143 (21): 2178–2189.

https://doi.org/10.1182/blood.2023023120

Published: 2024

Includes: Supplemental data

Journal Articles

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Blood (2023) 142 (20): 1724–1739.

https://doi.org/10.1182/blood.2023020400

Published: 2023

Includes: Supplemental data

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

Transcriptomic without Clinical Response to Menin Inhibition As a Mechanism of Upfront Resistance in Samples from Mutliply Relapsed Patients with KMT2A-Rearranged Leukemia

Leila Mahdavi, Haley Goodrow, Hongbo Xie, Alexandra Lenard, Fatemeh Alikarami, Simone Stefanie Riedel, Sarah K. Tasian, Gerald Wertheim, Sarah Skuli, Martin Carroll, Jerry McGeehan, Kathrin M. Bernt

Blood (2023) 142 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2023-180967

Published: 2023

NARROW

Precision Medicine for High-Risk Gene Fusions in Pediatric AML: a focus on KMT2A, NUP98, and GLIS2 Rearrangements

Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adults

Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML

APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A- rearranged , NUP98- rearranged , or NPM1- mutant Acute Leukemias

PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML

Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

KMT2A -Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial

Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2 -Rearranged Ph-like and Down Syndrome ALL

A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma

A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia

Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Transcriptomic without Clinical Response to Menin Inhibition As a Mechanism of Upfront Resistance in Samples from Mutliply Relapsed Patients with KMT2A-Rearranged Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only